Lower Doses of Bosentan in Combination With Sildenafil Might be Beneficial in Pulmonary Arterial Hypertension

BACKGROUND: Endothelin-receptor-antagonist, bosentan, has been found to improve the functional capacity and cardiopulmonary hemodynamics in Pulmonary Arterial Hypertension (PAH). Clinical trials have shown the preferable dosage of 125 mg, twice daily, regarding both efficacy and safety. OBJECTIVES:...

Descripción completa

Detalles Bibliográficos
Autores principales: Amin, Ahmad, Mohamadifar, Arezoo, Taghavi, Sepideh, Naderi, Nasim, Sadeghi, Hosnolah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Kowsar 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4588707/
https://www.ncbi.nlm.nih.gov/pubmed/26436071
http://dx.doi.org/10.5812/cardiovascmed.26487v2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4588707/
https://www.ncbi.nlm.nih.gov/pubmed/26436071
http://dx.doi.org/10.5812/cardiovascmed.26487v2

Ejemplares similares